Evidence map›Paper›PMID 39668103›Full record

ArticleEuropean urology2025

Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.

Elizabeth J Schafer, Mathieu Laversanne, Hyuna Sung, Isabelle Soerjomataram, Alberto Briganti, William Dahut, Freddie Bray, Ahmedin Jemal

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07614256 (A Multicenter Study of a Deep Learning Model Based on Spatial Registration of Multimodal Imaging and Digital Pathology for Predicting Clinically Significant Prostate Cancer), which is not on this map. Cited by 158 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07614256 recruitingnot on this map

A Multicenter Study of a Deep Learning Model Based on Spatial Registration of Multimodal Imaging and Digital Pathology for Predicting Clinically Significant Prostate Cancer

Typeobservational_patient_registrySponsorGuangxi Medical UniversityRan2025 to 2030Enrolled3,000ConditionsProstate Cancer (Diagnosis), Clinically Significant Prostate CancerArmsNo Intervention: Observational Cohort
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Detection rate of [Frontiers in medicine · 2026
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Article
  15. Article
  16. Cancer incidence and mortality trends from 2007 to 2021 in Milan.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elizabeth J SchaferSurveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA. Electronic address: elizabeth.schafer@cancer.org.
Mathieu LaversanneCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Hyuna SungSurveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
Isabelle SoerjomataramCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Alberto BrigantiDivision of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
William DahutOffice of the Chief Scientific Officer, American Cancer Society, Atlanta, GA, USA.
Freddie BrayCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Ahmedin JemalSurveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

BACKGROUND AND

objectiveOur aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.

methodsWe analyzed age-standardized PC incidence and mortality rates by country and region from the 2022 GLOBOCAN estimates and temporal trends in incidence (50 countries/territories) and mortality (59 countries/territories) rates using data from the Cancer Incidence in Five Continents series and the World Health Organization mortality database. KEY FINDINGS AND LIMITATIONS: Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.5-fold for mortality. The highest incidence rates were in Australia/New Zealand, North America, Northern Europe, and Latin America/Caribbean. The highest mortality rates were in sub-Saharan Africa and Latin America/Caribbean. During the most recent 5-yr period, incidence rates increased in 11 of the 50 countries included in the study and mortality rates increased in nine of 59 countries, mostly located in Africa, Asia, Latin America/Caribbean, and Central and Eastern Europe. Mortality rates decreased in 38 countries, largely located in Europe, Oceania, and Latin America/Caribbean. Limitations include the lack of data for low- and middle-income countries. CONCLUSIONS AND CLINICAL IMPLICATIONS: The increase in PC incidence and mortality rates in many countries in Africa, Asia, and Latin America/Caribbean may be because of increases in detection (incidence) and limited access to and availability of treatments (mortality only). The findings reinforce the importance of improving the health care infrastructure in these countries to mitigate the rising burden of PC.

Indexed as

Global HealthProstatic NeoplasmsHumansIncidenceMaleMortalityGlobal prostate cancerIncidence ratesMortality ratesTrends

Identifiers

PMID39668103
PMCPMC11862828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.